Carvedilolum [Latin]
Brand names,
Carvedilolum [Latin]
Analogs
Carvedilolum [Latin]
Brand Names Mixture
Carvedilolum [Latin]
Chemical_Formula
C24H26N2O4
Carvedilolum [Latin]
RX_link
http://www.rxlist.com/cgi/generic3/carvedilol.htm
Carvedilolum [Latin]
fda sheet
Carvedilolum [Latin]
msds (material safety sheet)
Carvedilolum [Latin]
Synthesis Reference
No information avaliable
Carvedilolum [Latin]
Molecular Weight
406.474 g/mol
Carvedilolum [Latin]
Melting Point
114-115 oC
Carvedilolum [Latin]
H2O Solubility
Practically insoluble (0.583 mg/L)
Carvedilolum [Latin]
State
Solid
Carvedilolum [Latin]
LogP
3.967
Carvedilolum [Latin]
Dosage Forms
Tablet
Carvedilolum [Latin]
Indication
For the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.
Carvedilolum [Latin]
Pharmacology
Carvedilol is a nonselective beta-adrenergic blocking agent with alpha1-blocking activity and is indicated for the treatment of hypertension and mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin. Carvedilol is a racemic mixture in which nonselective b-adrenoreceptor blocking activity is present in the S(-) enantiomer and a-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity. The effect of carvedilol's b-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces cardiac output in normal subjects; (2) reduces exercise-and/or isoproterenol-induced tachycardia and (3) reduces reflex orthostatic tachycardia.
Carvedilolum [Latin]
Absorption
Carvedilol is rapidly and extensively absorbed following oral administration, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
Carvedilolum [Latin]
side effects and Toxicity
Not expected to be toxic following ingestion.
Carvedilolum [Latin]
Patient Information
Patients taking COREG (Carvedilol) should be advised of the following:
- they should not interrupt or discontinue using COREG without a physician's advice.
- congestive heart failure patients should consult their physician if they experience signs or symptoms of
worsening heart failure such as weight gain or increasing shortness of breath.
- they may experience a drop in blood pressure when standing, resulting in dizziness and, rarely, fainting.
Patients should sit or lie down when these symptoms of lowered blood pressure occur.
- if patients experience dizziness or fatigue, they should avoid driving or hazardous tasks.
- they should consult a physician if they experience dizziness or faintness, in case the dosage should be
adjusted.
- they should take COREG with food.
- diabetic patients should report any changes in blood sugar levels to their physician.
- contact lens wearers may experience decreased lacrimation.
Carvedilolum [Latin]
Organisms Affected
Humans and other mammals